IMMUNE DESIGN CORP. (NASDAQ:IMDZ) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.
IMMUNE DESIGN CORP. (NASDAQ:IMDZ) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On December 16, 2016, Richard Kenney, M.D. resigned as Principal Medical Advisor of Immune Design Corp. (the “Company”). In connection with his resignation, Dr. Kenney will be eligible to receive the severance benefits provided in his Transition Agreement, dated June 28, 2016, a copy of which was filed with the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2016.
About IMMUNE DESIGN CORP. (NASDAQ:IMDZ)
Immune Design Corp. is a clinical stage immunotherapy company. The Company focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo. The ZVex vector is a delivery system based on a hybrid, re-engineered virus designed to carry the genetic information of selected tumor antigen in whole or selected epitopes selectively to dendritic cells (DCs) in the skin. When injected into a cancer patient, a ZVex-based product candidate is designed to interact only with these DCs, delivering the tumor antigen in the form of ribonucleic acid (RNA). GLA Adjuvant Systems (GLAAS) is a discovery platform that works in vivo and is based on a synthetic molecule called glucopyranosyl lipid A (GLA). IMMUNE DESIGN CORP. (NASDAQ:IMDZ) Recent Trading Information
IMMUNE DESIGN CORP. (NASDAQ:IMDZ) closed its last trading session up +0.35 at 6.75 with 159,396 shares trading hands.
Immune Design Corp. is a clinical stage immunotherapy company. The Company focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo. The ZVex vector is a delivery system based on a hybrid, re-engineered virus designed to carry the genetic information of selected tumor antigen in whole or selected epitopes selectively to dendritic cells (DCs) in the skin. When injected into a cancer patient, a ZVex-based product candidate is designed to interact only with these DCs, delivering the tumor antigen in the form of ribonucleic acid (RNA). GLA Adjuvant Systems (GLAAS) is a discovery platform that works in vivo and is based on a synthetic molecule called glucopyranosyl lipid A (GLA). IMMUNE DESIGN CORP. (NASDAQ:IMDZ) Recent Trading Information
IMMUNE DESIGN CORP. (NASDAQ:IMDZ) closed its last trading session up +0.35 at 6.75 with 159,396 shares trading hands.
